Higher Prevalence of Generalized Pustular Psoriasis in Asia? A Population-Based Study Using Claim Data in China and a Systematic Review
Dermatology · 2023 · 239 (2) · 195-205
DOI: 10.1159/000528850 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Dermatology, online erschienen am 02.01.2023. Verfasst von Jing-Nan Feng und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China. Hauptthemen laut MEDLINE: Psoriasis. Die Arbeit wurde bisher 26-mal zitiert (Crossref).
Abstract (Originalsprache)
Background
Few studies have reported the burden of generalized pustular psoriasis (GPP), a severe and potentially life-threatening skin disease, especially at a national level.
Objectives
The aim of this study is to estimate the nationwide burden of GPP in China and make a systemic review of the published data.
Methods
We conducted a population-based study using Urban Basic Medical Insurance in China from 2012 to 2016. GPP cases were identified by primary diagnoses including the international classification of Diseases codes (ICD-10: L40.1 and ICD-9: 694.3). A systematic review was conducted using relevant databases up to January 2022.
Results
The crude prevalence and incidence of GPP in 2016 were 1.403 (95% confidence interval [CI]: 1.115–1.691) and 0.629 (95% CI: 0.483–0.775) per 100,000 person-years, respectively. The rates were higher in males than in females for both prevalence (1.429 vs. 1.135) and incidence (0.635 vs. 0.520). The prevalence and incidence showed a bimodal age distribution, with the first peak occurring in the 0- to 3-year age-group and the second peak occurring in the 30- to 39-year age-group. The per capita total cost per year for 1 patient with GPP was 609.26 (± 45.77) US dollars. Seven studies were identified in a systematic review, according to which the prevalence (per 100,000) of GPP tended to be higher in Asian countries (0.746–8.178 in Japan and 12.230 in Korea) than in France (0.176), Sweden (6.25), and Brazil (0.7).
Conclusions
This is the largest study concerning the disease burden of GPP, and in this study, the prevalence seemed to be higher in Asia. Although the direct economic burden of GPP did not seem high during the study period, the future usage of biologics and the humanistic burden should also be considered for policy-related decision-making.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China.
- Department of Dermatology, Peking University Third Hospital, Beijing, China.
- Research Center of Clinical Epidemiology, Peking University Third Hospital, Beijing, China.
- Peking University Health Information Technology Co., Ltd., Beijing, China.
- Shanghai Songsheng Business Consulting Co., Ltd., Beijing, China.
- Institute for Artificial Intelligence, Peking University, Beijing, China.
Zitieren
APA
Feng, J. N., Guo, J. Z., Zhang, Q., Zhuo, L., Xu, L., Liu, L. L., Liu, G. Z., Wang, J. X., Gao, P., Wang, W. H., Zhan, S. Y., & Wang, S. F. (2023). Higher Prevalence of Generalized Pustular Psoriasis in Asia? A Population-Based Study Using Claim Data in China and a Systematic Review. Dermatology, 239(2), 195-205. https://doi.org/10.1159/000528850
Vancouver
Feng JN, Guo JZ, Zhang Q, Zhuo L, Xu L, Liu LL, et al. Higher Prevalence of Generalized Pustular Psoriasis in Asia? A Population-Based Study Using Claim Data in China and a Systematic Review. Dermatology. 2023;239(2):195-205. doi:10.1159/000528850
BibTeX
@article{Feng2023,
author = {Feng, Jing-Nan and Guo, Jin-Zhu and Zhang, Qian and Zhuo, Lin and Xu, Lu and Liu, Li-Li and Liu, Guo-Zhen and Wang, Jin-Xi and Gao, Pei and Wang, Wen-Hui and Zhan, Si-Yan and Wang, Sheng-Feng},
title = {Higher Prevalence of Generalized Pustular Psoriasis in Asia? A Population-Based Study Using Claim Data in China and a Systematic Review},
journal = {Dermatology},
year = {2023},
volume = {239},
number = {2},
pages = {195--205},
doi = {10.1159/000528850}
}
EUVIMED